A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics.
Lasagna
L
L
Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts 02111.
Shader
R I
RI
D001569:Benzodiazepines / Q000592:standards*; D004348:Drug Labeling; D017408:Guidelines as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration
D006993:Hypnotics and Sedatives; D001569:Benzodiazepines